Navigation Links
Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
Date:1/15/2008

Study Designed to Determine Statin Effects on Regression of Atherosclerosis

CLEVELAND, Jan. 15 /PRNewswire/ -- Cleveland Clinic researchers will coordinate the first head-to-head comparison of the two most powerful statin medications. The trial intends to begin enrollment as early as next week. Statins are the world's most commonly prescribed drugs and widely used to treat patients with elevated cholesterol levels.

The two drugs, atorvastatin (Lipitor) and rosuvastatin (Crestor), lower LDL ("bad") cholesterol and raise HDL ("good") cholesterol. But which drug is best for patients with heart disease? This study will seek to answer this important scientific question by measuring the rate of regression of coronary disease using intravascular ultrasound (IVUS), a technique that directly measures the amount of plaque in the coronary arteries.

The SATURN study (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN) will compare the ability of these two statins to stop the progression of atherosclerosis, the main cause of cardiovascular disease, over a two year treatment period.

SATURN, a multicenter, double-blind Phase IIIb trial, will use IVUS imaging to study approximately 1,300 patients at 150 hospitals in 20 countries worldwide. The trial is expected to be completed in 2011. Cleveland Clinic cardiologist Stephen J. Nicholls, M.D., PhD., will lead the trial.

Cleveland Clinic researchers have conducted two previous studies with IVUS looking at statins and the rate of atherosclerosis regression. Researchers have found a significant benefit with statins by intensively lowering LDL- cholesterol and the inflammatory marker C-reactive protein (CRP) and by raising levels of HDL cholesterol. SATURN aims to determine if differences in the ability of the different statins to lower LDL and raise HDL can promote regression (reduction in the amount of plaque in the coronary arteries).

About Cl
'/>"/>

SOURCE Cleveland Clinic
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
5. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Medical - SECRITT I Study to Evaluate Preventive Treatment ... Potentially Life Threatening Vulnerable Plaques, ... cardiology team led by Professor Patrick W. Serruys,successfully placed ... coronary artery of a 64-year-old man at Erasmus Medical,Center ...
... -- 10:00 a.m. EDT, 7:00 a.m. PDT ... -- 877-548-7901 ... http://www.isispharm.com , SAN DIEGO, June 30 Isis Pharmaceuticals,(Nasdaq: ISIS ) will conduct a ... TV-1102 clinical trial,and the ATL / TEVA / Isis relationship., -- ATL and TEVA announced clinical ...
Cached Medicine Technology:Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3Isis Pharmaceuticals Conference Call Notice 2
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
(Date:4/17/2014)... The world is less than 40 years away from ... people and governments, according to a top scientist at ... time in human history, food production will be limited ... water and energy," said Dr. Fred Davies, senior science ... issues could become as politically destabilizing by 2050 as ...
(Date:4/17/2014)... Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work has transformed ... a Fellow of the European Academy of Cancer Sciences., ... independent advisory body of highly distinguished oncologists and cancer ... caused by cancer in Europe. , Professor Johnston, whose ... move from the bottom of the UK league table ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
(Date:4/16/2014)... that fertility treatments are the leading cause of increases ... risk of premature birth, these results are not inevitable, ... . The article identifies six changes in policy ... births and prematurity, including expanding insurance coverage for in ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... Inc. (Nasdaq: SMBL ) announced today Steven Hughes, ... make a presentation at the Roth Capital Partners 21st Annual ... EST on Tuesday, February 17, 2009.Smart Balance,s presentation will be ... be able to ask questions, but listeners to the webcast ...
... from the clinical research community have already pledged ... American National Standards Institute (ANSI), coordinator ... is working to facilitate the use of electronic ... The Institute seeks the active engagement and financial ...
... Feb. 13 Dynatronics Corporation (Nasdaq: DYNT ) ... months ended December 31, 2008. Operating results showed significant improvement ... Pre-tax profit for the quarter ended December 31, 2008, improved ... the second quarter of the prior fiscal year. Net income ...
... BETHESDA, Md., Feb. 13 Micromet, Inc. (Nasdaq: MITI ), ... the ROTH 21st Annual Orange County Growth Stock Conference at the Ritz-Carlton ... The ROTH 21st Annual Orange County Growth Stock Conference, ... 4:30 pm Pacific Time, Place: The Ritz-Carlton ...
... SAN FRANCISCO, Feb. 13, 2009 New techniques used ... in the wild are yielding surprising results about hormones ... the social structure of a broader range of mammals. ... present findings at the AAAS meeting that examine social ...
... Applauds Senator Rockefeller and Representative Filner for Introducing ... Federation of Government Employees (AFGE) today applauded the ... the Senate Committee on Veterans, Affairs and Representative ... Veterans, Affairs for authoring legislation to amend Section ...
Cached Medicine News:Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 2Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 3Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 4Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 2Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 3Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 4Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 2Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 3Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 4Health News:Findings raise new questions about evolution of hormones in mammals 2Health News:Veterans' Affairs Employee Union Urges Congress to Strengthen Collective Bargaining Rights at VA Hospitals 2
... ML1 Manual Lensometer combines the traditional ... advantages, such as LED illumination and ... light source provides a clear green ... operated and completely cordless, the ML1 ...
... The Ultramatic RX Master Phoroptor ... - continues to be the industry standard ... that unmistakable feel of quality. The smooth ... of play in the mechanisms. The precise, ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... The Illuminated Phoroptor features lighted dials ... to perform refractions in the darkened setting ... pen light and leave the lights off ... features lighted sphere, cylinder power and cylinder ...
Medicine Products: